Drug Trial Radar · NCT07099430
A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
280
Planned (sponsor's estimate)
Start
Sep 5, 2025
Primary completion
Oct 30, 2027
Study completion Dec 30, 2027
Sponsor
- Lead sponsor
- Nanjing Leads Biolabs Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label, multicenter phase Ib/II study to evaluate the efficacy and safety of LBL-024 monotherapy or combination with toripalimab in patients with advanced melanoma,To evaluate the preliminary efficacy and safety of LBL-024 monotherapy and combination therapy in patients with advanced melanoma.
Conditions
- Advanced Melanoma
Interventions
LBL-024 for InjectionDrug
LBL-024 , Intravenous infusion.
Toripalimab InjectionDrug
Toripalimab , intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of adverse event (AE) and serious adverse event (SAE)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (90 days after drug withdrawal or before the start of new anti-tumor therapy)
- Objective Response Rate (ORR)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)
- Progression-free Survival(PFS)Time frame: From all subjects signed the informed consent form up to the completion of the follow-up period of drug withdrawal (28 days after drug withdrawal or before the start of new anti-tumor therapy)
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Beijing GoBroad Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Fujian Cancer Hospital
Fuzhou, Fujian, China · Recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Recruiting
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China · Recruiting
The First Hospital of Jilin University
Changchun, Jilin, China · Recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Recruiting
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China · Not yet recruiting
Shanxi Bethune Hospital
Taiyuan, Shanxi, China · Recruiting
The Second Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China · Not yet recruiting
West China Hospital of Sichuan University
Chengdu, Sichuan, China · Recruiting
Tianjin Medical University Cancer Institute &Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.